Both Suboxone and methadone are FDA-approved, evidence-based medications for opioid use disorder, and decades of research show they reduce overdose deaths and help people stabilize. The right choice depends on your medical history, your access to care, your insurance, and a conversation with a qualified medical provider after a full clinical evaluation. Suboxone is a buprenorphine-naloxone combination prescribed in office-based and telehealth settings. Methadone for opioid use disorder is a full opioid agonist dispensed through federally regulated opioid treatment programs.
This article is informational and not medical advice. Any decision to start, stop, or switch medication belongs to you and your provider.
Key Takeaways
- Suboxone and methadone are both evidence-based medications for opioid use disorder, with strong research showing they cut overdose risk and support long-term recovery.
- Suboxone is a partial opioid agonist (buprenorphine plus naloxone) typically prescribed in office-based or telehealth settings.
- Methadone is a full opioid agonist dispensed through federally regulated opioid treatment programs, with daily clinic visits common at the start.
- Long-acting buprenorphine injectables are an emerging option for some clients on the buprenorphine side of treatment.
- The right choice is the one you and a qualified medical provider arrive at through a full clinical evaluation.
What Is Suboxone?
Suboxone is a prescription medication that combines buprenorphine and naloxone, used to treat opioid use disorder. According to the National Institute on Drug Abuse, buprenorphine is a partial opioid agonist. It activates the brain’s opioid receptors, but only partially, which reduces cravings and withdrawal without producing the same high as full agonists. The naloxone component is included to deter misuse by injection.
Buprenorphine has what clinicians call a ceiling effect. After a certain dose, taking more doesn’t increase the opioid effect, which lowers the risk of respiratory depression and overdose compared with full agonist opioids, according to SAMHSA. Suboxone is typically prescribed in office-based settings: primary care offices, addiction medicine clinics, and telehealth visits. That access matters in rural counties across Maine where a daily clinic visit isn’t realistic.
What Is Methadone?
Methadone is a long-acting, full opioid agonist used to treat opioid use disorder and to manage pain. According to SAMHSA, methadone for opioid use disorder in the United States is dispensed exclusively through federally certified and state-licensed opioid treatment programs, often called OTPs or methadone clinics. The medication has been used to treat opioid use disorder since the 1960s and is one of the most studied treatments in addiction medicine.
As a full agonist, methadone activates opioid receptors completely at therapeutic doses. Research from the National Institute on Drug Abuse shows methadone reduces opioid cravings, blocks the euphoric effects of other opioids, and stabilizes the brain chemistry disrupted by long-term opioid use. The OTP delivery model is built around close monitoring, especially during induction.
Suboxone vs Methadone: The Key Differences
How Each Medication Works
Suboxone works as a partial opioid agonist. Buprenorphine binds to the same receptors that opioids like heroin, fentanyl, and oxycodone target, but it activates them only partially. That partial activation is enough to relieve withdrawal and cravings, and the ceiling effect limits how much the medication can suppress breathing or produce euphoria, per SAMHSA. The naloxone in Suboxone is minimally active when taken as prescribed, sublingually. It becomes active if the tablet is injected, which discourages misuse.
Methadone acts as a full opioid agonist. At a steady, properly titrated dose, it fully occupies opioid receptors, preventing withdrawal, reducing cravings, and blocking the effects of other opioids, according to the National Institute on Drug Abuse. Methadone has a long half-life, so most clients dose once a day. That long action is part of what makes it effective, and it’s also why the induction phase requires careful medical supervision.
Where and How You Get It
Suboxone is prescribed in office-based settings. As of late 2022, the Mainstreaming Addiction Treatment Act eliminated the previous X-waiver requirement: any clinician with a standard DEA registration can now prescribe buprenorphine for opioid use disorder, as SAMHSA has documented. Many providers also see clients via telehealth. The practical result is that Suboxone is generally easier to access in rural Maine, where the nearest opioid treatment program may be an hour or more away.
Methadone for opioid use disorder is dispensed through federally regulated opioid treatment programs, per SAMHSA. Especially in the first months of treatment, clients are typically required to come to the clinic daily for dosing. Take-home doses are introduced gradually as a client demonstrates stability. The clinic structure provides accountability, and it also requires geographic and scheduling access that not everyone has.
Safety and Overdose Considerations
Both medications are substantially safer than continued opioid use. The CDC has documented that medications for opioid use disorder cut overdose deaths and improve survival. The two medications carry different risk profiles when misused or combined with other substances.
Buprenorphine’s ceiling effect lowers the risk of fatal overdose when taken on its own, though combining it with benzodiazepines, alcohol, or other central nervous system depressants raises that risk significantly. Methadone is a full agonist, so dose-related respiratory depression is a real risk, particularly during induction or after a dose change. That’s part of why OTP protocols emphasize close monitoring early in treatment, as the National Institute on Drug Abuse describes.
Daily Structure and Flexibility
Suboxone’s office-based model gives clients flexibility. A monthly or quarterly visit, plus prescription refills picked up at a pharmacy, fits around a job, child care, or court-ordered programming. For someone managing probation requirements in Kennebec or York County, that flexibility can be the difference between staying in treatment and missing appointments.
Methadone’s clinic-based model offers a different kind of value: built-in daily structure and accountability. For some clients, especially in the earliest weeks of stabilization, that structure is exactly what works. For others, the daily clinic requirement is a barrier, especially if the nearest OTP is far away.
Who Tends to Do Well on Each
There’s no universal answer to which medication is better. The ASAM National Practice Guideline frames medication selection as an individualized decision based on the client’s history, preferences, co-occurring conditions, and treatment goals.
Clinicians often weigh factors like the severity and duration of opioid use, prior treatment history (including which medications have worked or not worked before), the presence of chronic pain, pregnancy considerations, other prescribed medications, transportation and scheduling realities, and the client’s own preference. A history of multiple buprenorphine attempts that haven’t stabilized someone may point toward methadone. A client with a job that won’t accommodate daily clinic visits, or who lives an hour from the nearest OTP, may do better on buprenorphine. The decision is a conversation, not a formula.
Why Medication-Assisted Treatment Works
Medication-assisted treatment, or MAT, combines FDA-approved medications with counseling and behavioral therapies. Research from the National Institute on Drug Abuse and SAMHSA consistently shows that MAT reduces opioid use, lowers overdose mortality, improves treatment retention, and supports employment and housing stability.
Opioid use disorder is a chronic medical condition that changes brain function over time. Treating it with medication is no different in principle from treating high blood pressure with antihypertensives or diabetes with insulin. The stigma around MAT, the idea that someone on Suboxone or methadone isn’t “really” in recovery, runs counter to the evidence. Harm reduction is clinical sophistication. The goal is a life that works: stable housing, steady work, repaired relationships, and reduced contact with the criminal legal system.
Long-Acting Injectable Options
For some clients on buprenorphine, long-acting injectables have changed what treatment looks like. Sublocade is a once-monthly subcutaneous injection of extended-release buprenorphine. Brixadi is also an extended-release buprenorphine injection, available in weekly and monthly formulations. Both are FDA-approved for moderate to severe opioid use disorder.
The appeal of injectable buprenorphine is that it removes the daily decision. A client coming out of incarceration with no stable housing doesn’t have to remember a pill every morning. The medication is in their system. Adherence, the single biggest predictor of MAT outcomes, becomes built in. Not every program offers every formulation, and the option to use an injectable depends on the prescriber, the program, and the client’s clinical picture. The question of whether a long-acting injectable is right for someone is part of the broader conversation with a qualified medical provider.
Making the Decision With a Provider
The choice between Suboxone, methadone, Vivitrol, or another medication for opioid use disorder belongs to you and a qualified medical provider after a full clinical evaluation. A good evaluation covers your substance use history, prior treatment, current health conditions, medications you’re already taking, mental health, social circumstances, and your own goals.
This article is informational and not medical advice. Don’t start, stop, or change any medication on your own. If you’re already on one medication and wondering about the other, the conversation to have is with your prescriber. They can help you understand whether a switch makes clinical sense and how to do it safely. If you’re in Maine and looking to start that conversation, call Enso Recovery of Augusta at (207) 245-1800 or Enso Recovery of Sanford at (207) 324-4054 for a full clinical evaluation.
Medication-Assisted Treatment in Maine
Enso Recovery is Maine’s pioneer in medication-assisted treatment across the justice-to-community continuum. The program was the first in Maine to bring MAT inside county jails, beginning treatment while clients are still incarcerated and transitioning them directly into outpatient care and sober living upon release. The model serves Augusta and Kennebec County, Sanford and York County, and the rural communities in between.
Enso provides buprenorphine-based MAT (Suboxone and other forms of buprenorphine), along with Vivitrol and oral naltrexone. Enso does not provide methadone; methadone for opioid use disorder is dispensed through federally regulated opioid treatment programs. Enso also does not provide on-site detox. The phased recovery model combines outpatient treatment, MARR-certified recovery residences, case management, and a step-down from intensive outpatient to outpatient. Telehealth is available. MaineCare and Medicaid are accepted at both Augusta and Sanford locations. For judges, probation officers, and corrections administrators evaluating MAT options for a client, this is a clinically rigorous, MaineCare-accepting pathway with built-in continuity of care.
Frequently Asked Questions
Is Suboxone or Methadone More Effective for Opioid Use Disorder?
Both are evidence-based and effective; neither is universally better. Research from the National Institute on Drug Abuse and SAMHSA shows both medications reduce opioid use and overdose risk when taken as prescribed. The right choice depends on the individual’s clinical picture, preferences, and access to care.
What Is the Main Difference Between Suboxone and Methadone?
Suboxone (buprenorphine-naloxone) is a partial opioid agonist with a ceiling effect, prescribed in office-based and telehealth settings. Methadone is a full opioid agonist for opioid use disorder dispensed through federally regulated opioid treatment programs, according to SAMHSA. The mechanism, the access model, and the daily structure are the main differences.
Why Is Methadone Only Available at Special Clinics?
Federal rules require methadone for opioid use disorder to be dispensed through certified opioid treatment programs, a framework established in the early 1970s and still in place today, as SAMHSA outlines. The structure was designed to provide close medical supervision, particularly during induction. Methadone is prescribed for pain management in regular medical settings, but for opioid use disorder treatment, the OTP requirement holds.
Does Enso Recovery Prescribe Methadone?
No. Enso provides buprenorphine-based MAT, including Suboxone, along with Vivitrol and oral naltrexone. Methadone for opioid use disorder is dispensed through federally regulated opioid treatment programs, not through office-based providers like Enso.
What Are Long-Acting Injectables Like Sublocade and Brixadi?
Sublocade and Brixadi are FDA-approved extended-release injectable formulations of buprenorphine. Sublocade is administered once monthly. Brixadi is available in weekly and monthly formulations. Both deliver a steady level of medication, which can improve adherence and remove the daily-dose decision. Whether an injectable is appropriate, and whether it’s available at a given program, are conversations to have with a qualified medical provider.
Can I Switch From One Medication to the Other?
Yes, switching is possible, and providers do it routinely when clinically indicated. The switch needs medical supervision because of how the two medications interact with opioid receptors. Starting buprenorphine while methadone is still in the system can trigger precipitated withdrawal. This is a conversation to have with a qualified medical provider.
Does MaineCare Cover Medication-Assisted Treatment?
Yes. MaineCare covers medication-assisted treatment, including buprenorphine and methadone formulations, when prescribed or dispensed by an enrolled provider. Enso Recovery accepts MaineCare at both the Augusta and Sanford locations.
Choosing a medication is a clinical decision, not a marketing one. If you, a family member, or a client you’re referring is considering MAT in Maine, call Enso Recovery of Augusta at (207) 245-1800 or Enso Recovery of Sanford at (207) 324-4054 to schedule a full clinical evaluation. MaineCare and Medicaid accepted.
Crisis and Emergency Resources
If you or someone you know is in a substance use or mental health crisis, help is available now. Contact the SAMHSA National Helpline at 1-800-662-HELP (4357) for free, confidential treatment referrals 24/7. Reach the 988 Suicide and Crisis Lifeline by calling or texting 988. The Crisis Text Line is available by texting HOME to 741741. For emergencies, call 911.